

# Chang Gung Medical Foundation Institutional Review Board

199, TUNG HWA NORTH ROAD,  
TAIPEI, TAIWAN, 10507  
REPUBLIC OF CHINA  
Tel: (03) 3196200  
Fax: (03) 3494549

Protocol Title : The role of epithelial mesenchymal transition in hepatocellular carcinoma with different etiologic factors- Application of OncoScan genechips

IRB No. : 104-3511C

Principal Investigator(s) : YU, MING-CHIN

Co-Investigator(s) : CHEN, MIN-FU, SEN-YUNG HSIEH

Duration of Approval: From 2015/05/25 TO 2016/04/30

Executing Institution: Chang Gung Memorial Hospital, Linko branch

Approved Protocol : 2015/04/28 Version 2

Approved Informed Consent : 2012/08/17 Version 3

Date of Approval : 2015/05/25

Frequency of Continuing Report: Once a year

※Next Deadline of Continuing Report: 2015/08/23. To facilitate the review, please submit the report two months before the deadline (or one month before the expiration of the trial if a continuing report shall be provided every three months) in order not to influence the principal investigator's right to conduct the research. In the case that failure or delay to submit a continuing report makes the IRB unable to determine the next trial period by the deadline, the trial shall not be continuously conducted. (This paragraph shall be provided if it is necessary to submit a continuing report.) If the Principal Investigator fails to submit a continuing report on time, rendering the Institutional Review Board unable to issue the next trial execution period before the previous trial execution period expires, all research activities, including the intervention or interaction with the participating trial subjects, must be suspended. Unless the Institutional Review Board considers that the continuation of trial intervention or trial participation is greatly beneficial to the trial subject's safety or in the best interest of the trial subject from a moral point of view, no new trial subject shall be included until the continuing report is formally approved.

※The IRB is organized and operates in accordance with Good Clinical Practice and the applicable laws and regulations.



<Tsang-Tang Hsieh, M.D.>

Chairman

Institutional Review Board

Chang Gung Medical Foundation